title: Early phase bronchoconstriction in the mouse requires allergen-specific IgG.
abstract: Allergen provocation of allergic asthma patients is often characterized by an initial period of bronchoconstriction, or early phase reaction (EPR), that leads to maximal airway narrowing within 15-30 min, followed by a recovery period returning airway function to baseline within 1-2 h. In this study, we used a defined OVA provocation model and mice deficient for specific leukocyte populations to investigate the cellular/molecular origins of the EPR. OVA-sensitized/challenged wild-type (C57BL/6J) mice displayed an EPR following OVA provocation. However, this response was absent in gene knockout animals deficient of either B or T cells. Moreover, transfer of OVA-specific IgG, but not IgE, before the OVA provocation, was capable of inducing the EPR in both strains of lymphocyte-deficient mice. Interestingly, an EPR was also observed in sensitized/challenged mast cell-deficient mice following an OVA provocation. These data show that the EPR in the mouse is an immunologically based pathophysiological response that requires allergen-specific IgG but occurs independent of mast cell activities. Thus, in the mouse the initial period of bronchoconstriction following allergen exposure may involve neither mast cells nor IgE-mediated events.
authors.affiliation: Divisions of Hematology/Oncology and Pulmonary Medicine, Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Crosby
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Cieslewicz
authors.forename: Michael
authors.initials: M
authors.lastname: Borchers
authors.forename: Edie
authors.initials: E
authors.lastname: Hines
authors.forename: Patricia
authors.initials: P
authors.lastname: Carrigan
authors.forename: James J
authors.initials: JJ
authors.lastname: Lee
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Lee
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D000918:Antibody Specificity / Q000235:genetics; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D016084:Bronchoconstriction / Q000235:genetics / Q000276:immunology*; D003433:Crosses, Genetic; D007073:Immunoglobulin E / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000096:biosynthesis / Q000502:physiology*; D007274:Injections, Intraperitoneal; D008231:Lymphopenia / Q000235:genetics / Q000276:immunology; D008407:Mast Cells / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D013997:Time Factors
chemical_list: D000336:Aerosols; D000485:Allergens; D007074:Immunoglobulin G; D007073:Immunoglobulin E; D010047:Ovalbumin